Fulcrum Therapeutics Appoints Christopher Moxham, Ph.D. as SVP, Discovery
Cambridge, Mass., February 20, 2019 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, today announced further growth of their leadership team with the appointment of Christopher Moxham, Ph.D. as senior vice president of discovery.
Moxham has over 20 years of drug discovery experience, primarily at Eli Lilly and Company where he most recently served as vice president, quantitative biology. In this role, he helped grow Lilly’s oncology pipeline, developed critical biopharma and academic partnerships and established a state-of-the-art lab facility focused on preclinical and translational research. Previously, he was associate vice president, oncology research at Lilly where he established and led the company’s biomarker group. Moxham began his tenure at Lilly as a research scientist and received several awards from the company, including the Lilly Research Laboratories President’s Award and the Eli Lilly and Co. Global Quality Advocate Award. He also spent two years as a senior research fellow at Merck, where he supported a portfolio of projects centered on Alzheimer’s disease and led work that resulted in a clinical candidate. Moxham serves on the external review boards of the Long Island Bioscience Hub and the Alzheimer’s Drug Discovery Foundation, and on the advisory board of Science Exchange. He has a B.S. in biological sciences from Cornell University and a Ph.D. in molecular and cellular pharmacology from the State University of New York at Stony Brook. He also conducted postdoctoral training at SUNY Stony Brook, sponsored by the National Institutes of Health.
“Fulcrum’s product engine has demonstrated enormous potential to leverage unique insights into disease biology to address the root cause of genetic diseases, and the team’s patientfocused approach creates a smooth path through clinical development,” Moxham said. “I look forward to working with this talented team to expand and progress their research pipeline.”
About Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes. Fulcrum, headquartered in Cambridge, Mass., has raised $140 million from two rounds of funding. Investors include Foresite Capital, Fidelity Management and Research Company, 6 Dimensions Capital, Casdin Capital, Sanofi Ventures, Section 32, NS Investments, entities affiliated with Leerink Partners and undisclosed institutional investors, as well as founding investor Third Rock Ventures. Fulcrum was launched in 2016 and named a “Fierce 15” company later that year. For more information, please visit www.fulcrumtx.com.
Ten Bridge Communications